Construction method of granulomatous mastitis rat model

By constructing a rat model of granulomatous mastitis with elevated prolactin levels and secretion accumulation, the problem of inreliable model design in the prior art was solved, the similarity with human disease manifestations was achieved, and disease research was promoted. Development of new therapeutic technologies.

CN118948482APending Publication Date: 2024-11-15LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411321725.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, the rejection between human tissue and animal tissue is ignored when constructing an animal model of granulomatous mastitis, making it difficult to clarify the pathogenic factors and mechanisms, and the model design is not reliable enough.

Method used

A method of constructing a rat model of granulomatous mastitis was used to adaptive feeding, hair removal, anesthesia, intraperitoneal injection of oxytocin, and make a milky white oil-in-lactane suspension, and according to specific doses and Subcutaneous injection of gastrofuan and suspension was performed at time points to form a model with "elevated prolactin levels" and "secret stagnation" of the key factors in the pathogenesis.

Benefits of technology

The constructed model has single and clear modeling conditions, and the skin manifestations, changes in mass size, serum PRL and pathological morphological indicators in rats are similar to those in human diseases. It has important standardization and standardization significance, which helps disease research and novel drugs. Development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948482A_ABST
    Figure CN118948482A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical research, and discloses a construction method of a granulomatous mastitis rat model, which comprises the following steps: step 1, selecting a Wistar rat in a lactation period, performing adaptive feeding for 1 week, and performing ultraviolet disinfection on all experimental articles including the rat for 20 minutes; 2, anesthetizing the rats in the lactation period, fixing the rats on an operation plate in a super clean bench by using an adhesive tape, quickly depilating the abdomen of the rats by using depilating paste, cleaning the hair, and disinfecting the exposed skin of the chest and abdomen by using alcohol cotton balls; 3, injecting 2ml / kg of oxytocin into the intraperitoneal cavity of the rat, and after 10 minutes, wearing sterile gloves to take milk, and 4, uniformly mixing the milk of the rat with a Freund's adjuvant in a super clean bench according to a ratio of 1: 1, placing the mixture on a shaking table at 4 DEG C overnight to prepare a milky white emulsion-in-oil suspension which is divided into a suspension 1: a complete Freund's adjuvant added by the milk, a suspension 2: a complete Freund's adjuvant added by the milk, a suspension 3: a complete Freund's adjuvant added by the milk, and a suspension 4: a complete Freund's adjuvant added by the suspension 2: a complete Freund's adjuvant added by the milk. 5, selecting 6-8-week-old female non-pregnant Wistar rats, carrying out back hypodermic injection of pestofurone at 9 o'clock in the morning every day according to the dosage of 30 mg / kg, continuously carrying out 2 weeks, respectively injecting 0.2 mL of the suspension 1 into each rat through a third pair of mammary glands and a fourth pair of mammary glands on the first day of an experiment, respectively injecting 0.2 mL of the suspension 2 into each rat on the seventh day and the fourteenth day, continuously feeding the rats for 2 weeks, and feeding the rats into the female non-pregnant Wistar rats according to the dosage of 0.2 mL of the suspension 1 into the female non-pregnant Wistar rats after the rats are continuously fed for 2 weeks. The granuloma mastitis rat model is obtained. The method has the advantages that the method is simple in process, key factors of prolactin level increase and secretion deposition are used as modeling conditions, modeling factors are single and clear, indexes such as rat skin expression, lump size change, serum PRL and pathological morphology have certain reference value, and the method has important significance on standardization and standardization of animal models.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medical research, and in particular to a method for constructing a granulomatous mastitis rat model. Background Art

[0002] Granulomatous mastitis is a type of benign chronic inflammatory breast disease with a long course. Its clinical manifestations are complex and varied, the course is long, and it is prone to recurrence. It is called "immortal cancer". In clinical work, it is easily confused with inflammatory breast cancer. It has been gradually increasing in recent years. At present, there are relatively few methods for constructing animal models of granulomatous mastitis. Some studies have established disease models by injecting human granulomatous mastitis pathological tissue homogenates into rodents, but have ignored the rejection of human tissues and animal tissues. The composition of these pathological tissues is complex, and it is difficult to clarify the exact pathogenic factors and mechanisms of the disease. It also cannot meet the reliability principle of animal model design. Therefore, a method for constructing a rat model of granulomatous mastitis is proposed to solve the above-mentioned problems. Summary of the invention

[0003] The technical problem to be solved by the present invention is to provide a method for constructing a granulomatous mastitis rat model in view of the deficiencies in the above-mentioned prior art.

[0004] In order to solve the above technical problems, the technical solution adopted by the present invention is: a method for constructing a granulomatous mastitis rat model, comprising the following steps:

[0005] Step 1: Select lactating Wistar rats, and after one week of adaptive feeding, all experimental objects including rats are sterilized with ultraviolet light for 20 minutes;

[0006] Step 2: After the lactating rats are anesthetized, they are fixed on the operating board in the clean bench with adhesive tape, and the abdomen of the rats is quickly depilated with depilatory cream. After the hair is cleaned, the exposed skin of the chest and abdomen is disinfected with alcohol cotton balls;

[0007] Step 3: Then, 2 ml / kg of oxytocin was injected into the rats’ peritoneum. After 10 minutes, the rats were put on sterile gloves to collect milk.

[0008] Step 4: Rat milk was mixed with Freund's adjuvant in a 1:1 ratio in a clean bench, and placed on a shaker at 4°C overnight to prepare a milky white oil-in-emulsion suspension, which was divided into: Suspension 1: milk plus complete Freund's adjuvant; Suspension 2: milk plus incomplete Freund's adjuvant;

[0009] Step 5. Select 6-8 week old female non-pregnant Wistar rats, inject metoclopramide subcutaneously into the back of each rat at a dose of 30 mg / kg at 9 am every day for 2 consecutive weeks, and on the first day of the experiment, inject 0.2 mL of suspension 1 into the 3rd and 4th mammary glands of each rat, respectively, and inject 0.2 mL of suspension 2 again on the 7th and 14th days, respectively. After the rats are fed for 2 weeks, a rat model of granulomatous mastitis is obtained.

[0010] Preferably, the rats selected in each step are all SPF grade.

[0011] Preferably, the research experiment uses an SPF-level laboratory, wherein the temperature of the SPF-level laboratory is 18-24° C., the humidity is 50%-70%, and the lighting is alternating for 12 hours per day.

[0012] Preferably, rats are fed with ordinary feed and sterile water during the experiment.

[0013] The present invention adopts the above technical solution to bring the following beneficial effects:

[0014] 1. This method for constructing a rat model of granulomatous mastitis uses the key factors of the disease, "elevated prolactin level" and "secretion accumulation", as modeling conditions. The modeling factors are single and clear, and indicators such as rat skin manifestations, changes in tumor size, serum PRL and pathological morphology have certain reference value, which is of great significance to the normalization of animal models.

[0015] 2. The method for constructing a rat model of granulomatous mastitis. The various observation indicators of rats have great similarities with the clinical and pathological manifestations of human diseases. The dynamic observation of animal models is helpful to fully understand the occurrence and development of the disease, and to study the etiology, pathogenesis and prevention and control measures of the disease on this basis. It is of great significance to answer the susceptibility of specific populations to the disease, and the development of new drugs and new treatment technologies. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 A schematic diagram of the process flow of the model construction of the present invention;

[0017] Figure 2 This is a diagram showing changes in breast masses in a rat model of granulomatous mastitis according to the present invention;

[0018] Figure 3 This is a diagram showing granuloma formation and inflammatory cell infiltration in breast lesion tissue under a microscope of the present invention. DETAILED DESCRIPTION

[0019] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0020] In the description of the present invention, it is necessary to understand that the terms "upper", "lower", "front", "back", "left", "right", "top", "bottom", "inside", "outside", etc., indicating orientations or positional relationships, are based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as a limitation on the present invention.

[0021] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installation", "connection" and "setting" should be understood in a broad sense, for example, they can be fixedly connected or set, or detachably connected or set, or integrally connected or set. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0022] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "several" is two or more, unless otherwise clearly and specifically defined.

[0023] An embodiment of the present invention is:

[0024] S1. Animal grouping: 24 SPF healthy female non-pregnant Wistar rats aged 6-8 weeks were prepared. They were allowed to freely consume a standard animal diet before the experiment and adapted to the environment for 1 week. Then, they were randomly stratified and grouped according to body weight using the Rand function of the Excel spreadsheet. There were four groups in total, namely the normal group (Control), metoclopramide group (WG), model I group (MG-I), and model II group (MG-II), with 6 rats in each group.

[0025] S2. Model construction

[0026] S2.1. Normal group: rats were raised normally for 4 weeks.

[0027] S2.2, Metoclopramide group (WG): 30 mg / kg of metoclopramide was injected subcutaneously in the back of rats once a day for 2 consecutive weeks. After the rats were kept for 2 weeks, relevant indicators were tested to obtain the WG rat model.

[0028] S2.3, Model I Group (MG-I):

[0029] S2.31. After anesthesia, the rats were placed in a supine position. The third and fourth pairs of mammary glands and their surrounding areas were depilated with depilatory cream. The exposed skin of the chest and abdomen was thoroughly disinfected with alcohol cotton balls.

[0030] S2.32. On the first day of the experiment, each rat was injected with 0.2 mL of suspension 1 through the third and fourth pairs of mammary fat pads, and on the seventh day, 0.2 mL of suspension 2 was injected;

[0031] S2.33, 30 mg / kg of metoclopramide was injected subcutaneously on the back of rats once a day for 2 weeks;

[0032] S2.34. After continuing to feed the rats for 2 weeks, relevant indicators were tested to obtain the MG-I rat model.

[0033] S2.4, Model II Group (MG-II):

[0034] S2.41. After anesthesia, the rats were placed in a supine position. The third and fourth pairs of mammary glands and their surrounding areas on the abdomen of the rats were depilated with depilatory cream. The exposed skin on the chest and abdomen was thoroughly disinfected with alcohol cotton balls.

[0035] S2.42. On the first day of the experiment, each rat was injected with 0.2 mL of suspension 1 through the third and fourth pairs of mammary fat pads, and on the seventh and 14th days, 0.2 mL of suspension 2 was injected respectively;

[0036] S2.43, 30 mg / kg of metoclopramide was injected subcutaneously on the back of rats once a day for 2 weeks;

[0037] S2.44. After continuing to feed the rats for 2 weeks, relevant indicators were tested to obtain the MG-II rat model.

[0038] See also Figure 1-3 In another embodiment of the present invention, model index detection and analysis

[0039] All statistical analyses were performed using IBM SPSS Statistics 26. If the difference was not statistically significant, t test was used for comparison analysis, otherwise Mann Whitney test was used, and the results were expressed as median (M) and interquartile range (Q1, Q3). For comparison among multiple groups, data were normally distributed and had equal variances, and variance analysis was used, otherwise Kruskal-Wallis H test was performed, and P value < 0.05 indicated statistically significant differences.

[0040] (1) Detection of breast lump size

[0041] The mammary gland masses of rats in groups MG-I and MG-II in Example 1 were measured using a vernier caliper. Before the measurement, the rats were fixed with the left hand. After the rats were firmly held, the long and short diameters of the mammary gland masses were measured respectively, and the readings displayed on the vernier caliper were recorded. The measurement was performed three times and recorded, with a fixed person measuring each time. The measurement results are shown in Tables 1 and Figure 2 .

[0042] Time (w) n MG-I group MG-II Group 1 6 204.57±34.46 239.42±33.50 2 6 1826.96±137.45 1886.17±157.95 3 6 2139.72±179.45 1628.51±131.83 4 6 1639.21±274.16 <![CDATA[4262.62±476.00 ** ]]>

[0043] Note: **P<0.01 compared with MG-I group.

[0044] From Table 1 and Figure 2 It can be seen that there was no statistical difference in the size of breast lumps between the MG-I group and the MG-II group at the 1st, 2nd, and 3rd week of the experiment (P>0.05); at the 4th week of the experiment, the MG-II group had a larger mass than the MG-I group, and the difference was statistically significant (P<0.01). Starting from the 4th week of the experiment, the breast lumps in the MG-I group showed a downward trend, while the breast lumps in the MG-II group showed a significant upward trend, and the growth of the lumps could maintain a certain stability. Irregular breast lumps are the most common clinical signs of granulomatous mastitis. The breast lumps of rats in the MG-II group gradually increased over time, and ulceration of the lumps occurred at different stages of the disease, which is highly similar to the clinical manifestations of human granulomatous mastitis patients.

[0045] (2) Serum prolactin test

[0046] Blood was collected from the model rats in each group of Example 1 through the orbital venous plexus at the 0th, 1st, 2nd, 3rd and 4th weeks of the experiment, and the changes of prolactin in rats at different time points were detected by ELISA. Elevated serum prolactin level is a key factor in the onset of granulomatous mastitis. Metoclopramide promotes prolactin secretion, has a high application rate and high safety in human and animal experiments. Therefore, metoclopramide was selected as an inducer for increasing animal serum prolactin.

[0047] The changes of serum prolactin in rats treated with metoclopramide at different time periods are shown in Table 2

[0048] Time (w) Prolactin (ng / L) 0 287.20±12.66 1 <![CDATA[387.00±15.31 ** ]]> 2 <![CDATA[458.60±20.70 *** ]]> 3 <![CDATA[432.20±47.20 *** ]]> 4 <![CDATA[387.10±12.09 ** ]]>

[0049] Note: Compared with before medication, **P<0.01, ***P<0.001.

[0050] As shown in Table 2, compared with the level before subcutaneous injection of metoclopramide, the serum prolactin levels of rats in the WG group, MG-I group, and MG-II group were all increased. And as the medication time prolonged, the prolactin level gradually increased. Even after drug withdrawal, the prolactin level of rats could still be maintained for a period of time. This shows that metoclopramide can effectively induce an increase in serum prolactin levels and effectively construct a rat hyperprolactemia model.

[0051] (3) Breast pathology testing

[0052] After the model rats in each group of Example 1 were anesthetized and killed, the third and fourth pairs of mammary glands of the rats were completely separated, fixed with paraformaldehyde, and soaked in physiological saline. After hematoxylin-eosin staining, the granuloma formation and inflammatory cell infiltration in the mammary gland lesions were observed under a microscope. Figure 3 shown.

[0053] Depend on Figure 3 It can be seen that the microscopic structure of the mammary ducts and lobules in the Comtrol group was clear, and most of the field of view was adipose tissue. No clear infiltration of lymphocytes, foamy tissue cells, plasma cells, multinuclear giant cells, macrophages, etc. was observed. In the WG group, the mammary lobules were hyperplastic, the number of alveoli and lobules increased, the alveoli and ducts were slightly dilated, and a small amount of red-stained secretions were observed; no obvious infiltration of inflammatory cells such as plasma cells and neutrophils was observed around the mammary lobules and milk ducts. In the WG-I group, no obvious granuloma formation was observed, a small amount of lymphocyte infiltration was observed around, and the lumen was empty or red-stained secretions were observed. In the lesion area of ​​the WG-II group, multiple foci were scattered and epithelial cells of varying sizes formed granulomatous nodules with various inflammatory cell infiltrations, mainly lymphocytes, and neutrophils, plasma cells, multinuclear giant cells, etc. were also observed. The pathological manifestations are similar to those of human granulomatous mastitis.

[0054] The above-mentioned implementation modes are only preferred implementation modes of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and substitutions made by technicians in this field on the basis of the present invention shall fall within the scope of protection required by the present invention.

[0055] The present invention provides a method for constructing a granulomatous mastitis rat model. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A method for constructing a granulomatous mastitis rat model, characterized in that: The following steps are involved: Step 1: Select lactating Wistar rats, and after one week of adaptive feeding, all experimental objects including rats are sterilized with ultraviolet light for 20 minutes; Step 2: After the lactating rats are anesthetized, they are fixed on the operating board in the clean bench with adhesive tape, and the abdomen of the rats is quickly depilated with depilatory cream. After the hair is cleaned, the exposed skin of the chest and abdomen is disinfected with alcohol cotton balls; Step 3: Then, 2 ml / kg of oxytocin was injected into the rats’ peritoneum. After 10 minutes, the rats were put on sterile gloves to collect milk. Step 4: Rat milk was mixed with Freund's adjuvant in a 1:1 ratio in a clean bench, and placed on a shaker at 4°C overnight to prepare a milky white oil-in-emulsion suspension, which was divided into: Suspension 1: milk plus complete Freund's adjuvant; Suspension 2: milk plus incomplete Freund's adjuvant; Step 5. Select 6-8 week old female non-pregnant Wistar rats, inject metoclopramide subcutaneously into the back of each rat at a dose of 30 mg / kg at 9 am every day for 2 consecutive weeks, and on the first day of the experiment, inject 0.2 mL of suspension 1 into the 3rd and 4th mammary glands of each rat, respectively, and inject 0.2 mL of suspension 2 again on the 7th and 14th days, respectively. After the rats are fed for 2 weeks, a rat model of granulomatous mastitis is obtained.

2. The method for constructing a granulomatous mastitis rat model according to claim 1, characterized in that: The rats selected in each step were all SPF grade.

3. The method for constructing a granulomatous mastitis rat model according to claim 1, characterized in that: The research experiment selected an SPF-level laboratory, wherein the temperature of the SPF-level laboratory was 18-24° C., the humidity was 50%-70%, and the lighting was alternating for 12 hours per day.

4. The method for constructing a granulomatous mastitis rat model according to claim 1, characterized in that: During the experiment, rats were fed with ordinary feed and sterile water.

Citation Information

Cited By

  • Granular mastitis animal model and construction method thereof

    CN122516348A

  • An animal model of granulomatous mastitis and its construction method

    CN122516348B